Abstract:
Disclosed herein are methods useful for detecting and/or quantifying tropolone in samples, e.g., generated during the production of and in final formulations of a product, e.g., a recombinant protein, e.g., an antibody. Tropolone and derivatives thereof (cycloheptatriene ketones) are separated from a mixture by adding a partially or fully fluorinated alkyl or aryl (e.g. pentafluorophenylpropyl), which (covalently) binds the tropolone-like compound. Then it is assayed via UV or tandem mass spectrometry. A reaction mixture of tropolone-like compounds and fluorinated alkyl or aryl is also disclosed.
Abstract:
Excellent 12-lipoxygenase inhibitors containing as the active ingredient tropolone derivatives of the general formula (1) or salts thereof. In said formula wherein R is hydrogen or optionally substituted C3-10 alkenyl; R is hydrogen, C1-6 alkyl, optionally substituted C3-10 alkenyl, or alkynyl; R is hydrogen; R is hydrogen or C1-6 alkyl; and R is hydrogen or a group of the general formula (2): -(CH2)nNR R (wherein n is an integer of 1 to 6; and R and R are each independently hydrogen, alkyl, or aralkyl, or alternatively R and R together with the nitrogen atom adjacent thereto may represent optionally substituted 5- or 6-membered cyclic amino), with the proviso that the compound wherein R , R , R , R and R are simultaneously hydrogen is excepted.
Abstract translation:含有作为活性成分的通式(1)的托普洛尔衍生物或其盐的优异的12-脂氧合酶抑制剂。 在所述式中,其中R 1是氢或任选取代的C 3-10烯基; R 2是氢,C 1-6烷基,任选取代的C 3-10烯基或炔基; R 3是氢; R 4是氢或C 1-6烷基; 和R 5为氢或通式(2)的基团: - (CH 2)n NR 6 R 7(其中n为1至6的整数; R 6和R 7为 各自独立地为氢,烷基或芳烷基,或者R 6和R 7与其相邻的氮原子一起可以表示任选取代的5-或6-元环状氨基),条件是其中 R 1,R 2,R 3,R 4和R 5同时为氢。
Abstract:
The present disclosure relates to inhibitors of herpesvirus nucleic acid metabolism and inhibitors of Hepatitis B virus. Also provided are methods of treatment using these agents.
Abstract:
Disclosed is the use of benzotropolone derivatives of formula (1), wherein R1, R2 and R7 independently from each other are hydrogen; C1-C3alkyl; or COR8; R3 is hydrogen; or COOR9 R4 is hydrogen; or C1-C3alkyl; R5 is hydrogen; hydroxy; C1-C3-alkoxy; or -0-(CO)-R10; R6 is hydrogen; C1-C3alkyl; or COR8; or R5 and R6 together may form a five or six membered ring; or R6 and R7 together form a five or six membered ring; and R8, R9, R10 independently of each other are C1-C30alkyl; for protecting body-care and household products from photolytic and oxidative degradation.
Abstract:
Disclosed are a series of compounds or their tautomers having a general structure represented by Formula la or lb and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula la or lb compounds or tautomers or pharmaceutically acceptable salts thereof.
Abstract:
A process for producing hinokitiol which comprises obtaining 1-isopropylcyclopentadiene from cyclopentadiene and an isopropylating agent represented by the general formula R-X (wherein R represents isopropyl; and X represents halogeno, etc.) (the step 1); reacting the obtained product with a dihaloketene to give a ketene-adduct (the step 2); and then decomposing this ketene-adduct (the step 3); wherein the above step 1 involves the following three steps: (a) the step of preparing a cyclopentadienyl metal; (b) the step of isopropylating the cyclopentadienyl metal in an aprotic polar solvent to give isopropylcyclopentadiene; and (c) the step of isomerizing 5-isopropylcyclopentadiene contained in the product selectively into 1-isopropylcyclopentadiene under heating.